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Abstract
The basolateral nucleus of the amygdala (BLA) plays a key role in emotional arousal and anxiety, and expresses high levels of
corticotropin-releasing factor receptor (CRFR)1. In rat brain slices, we have recently shown that afferent activation of the BLA is
increased following application of exogenous corticotropin-releasing factor (CRF). Here we examined the impact of chronic
unpredictable stress (CUS) on this effect of CRF and whether blockade of CRFR1 could prevent stress-induced changes in the
electrophysiological response, the animal’s behavior and in cell proliferation in the hippocampus. The behavior of the rats was
monitored via a series of tests that formed part of the CUS. Electrophysiological measures of the BLA response to CRF, cell
proliferation in the dentate gyrus and the expression of CRF and CRFR1 mRNA in amygdaloid nuclei were determined ex vivo after
completion of the CUS. CRF-induced potentiation of afferent activation of the BLA was reduced in rats exposed to CUS, an effect that
was inhibited by chronic antagonism of CRFR1. Furthermore, the reduction in BLA response to CRF was correlated with the anxiety
trait of the animals, determined prior to initiation of the CUS. These results implicate CRFR1 in chronic stress-induced alterations in
amygdala function and behavior. Furthermore, they show that CRFR1 antagonists can prevent changes induced by chronic stress, in
particular in those animals that are highly anxious.
Introduction
Corticotropin-releasing factor (CRF) is an essential mediator of the
behavioral, endocrine and autonomic responses to stress (Dunn &
Berridge, 1990). The effects of CRF are mediated by two receptors,
corticotropin-releasing factor receptor (CRFR)1 and CRFR2, with the
former most abundant in the central nervous system. Strong evidence
supports a key role for the dysregulation of CRF pathways in anxiety
and depression in humans (Holsboer, 1999; Van Den Eede et al., 2005)
and animals (Dunn & Berridge, 1990; Koob & Heinrichs, 1999).
The central nucleus of the amygdala (CeA) is the major extrahy-
pothalamic location of CRF-containing neurons that release CRF in
response to stress (Merlo Pich et al., 1995). The basolateral nucleus of
the amygdala (BLA) has been shown to play a key role in emotional
arousal and stress-induced, CRF-mediated modulation of cognitive
processes (Roozendaal et al., 2002, 2004; McGaugh, 2004). Magno-
cellular neurons in the BLA express high levels of CRFR1 (Chen
et al., 2000; Van Pett et al., 2000) and project to areas such as the
hippocampus, where they contribute to the consolidation of emotional
memories (Pare´, 2003). Activation of CRFR1 was shown to increase
the excitability of these projection neurons (Rainnie et al., 1992) and
thus the release of CRF in the BLA has been postulated to contribute
to stress-induced alterations in affective behavior, including anxiety
states linked to chronic stress (Rainnie et al., 2004). Consistent with
this hypothesis, repeated activation of the BLA or repetitive adminis-
tration of subthreshold doses of CRF results in altered sensitivity of
BLA neurons to further stimulation and the development of a chronic
anxiety-like state (Sajdyk et al., 1999).
We recently found that the amplitude of ﬁeld post-synaptic potentials
(fPSPs) recorded in the BLA and evoked by stimulation of the lateral
nucleus of the amygdala was increased following application of
exogenous CRF (Ugolini et al., 2008). The effect was mediated by
CRFR1 and by downstream activation of protein kinase C, and is
reminiscent of CRF-induced long-term potentiation observed in the
hippocampus,which is alsomediated byCRFR1 (Blank et al., 2002). The
effect was also consistent with neurochemical (Dube et al., 2000) and
electrophysiological (Rainnie et al., 2004) evidence that indicated an
activation of the BLA following in-vivo central (intracerebroventricular
or intra-amygdala) administration of CRF. In the present study, we used a
chronic unpredictable stress (CUS) model in rats to evaluate whether the
responsiveness of theBLA toCRFmight be affected by stress. In parallel,
we examined the behavior of animals exposed to the CUS via tests that
formed part of the unpredictable stress procedure. We hypothesized that
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the CUS procedure might blunt the electrophysiological response of the
BLAto exogenousCRFand that thiswouldbe associatedwith behavioral
changes in the animals. In order to determine whether electrophysiolog-
ical and ⁄ or behavioral changes were associated with altered expression
of the CRF system, we also investigated the impact of CUS on the
expression of CRFR1 and CRF peptide mRNA in the amygdala.
Antagonists of CRFR1 can reduce the stress-induced behavioral
response in rodent models of depression (Arborelius et al., 1999, 2000;
Bale & Vale, 2003). Moreover, a non-peptide CRFR1 antagonist, 3-[6-
(dimethylamino)-4-methyl-pyrid-3-yl]-2,5-dimethyl-N,N-dipropyl-pyr-
azolo[2,3-a]pyrimidin-7-amine (NBI30775) (also known as R121919),
has been shown to have beneﬁcial effects on depressive symptoms in
patients (Zobel et al., 2000). Therefore, in a further experiment, we
examined the ability of this antagonist, when given chronically during
the CUS procedure, to prevent electrophysiological and behavioral
changes. In addition, as reductions in hippocampal neurogenesis and
cell proliferation have been repeatedly associated with chronic stress
and depression (Duman, 2004), we also examined changes in cell
proliferation in the dentate gyrus following CUS and the ability of
NBI30775 to prevent any changes that might be seen.
Finally, although chronic stress is likely to contribute to the
development of depression, there is considerable variability in the
susceptibility of individuals to the adverse effects of stress. Individual
differences in personality traits are associated with both resilience to
stress and stress-induced depression (Southwick et al., 2005; Levinson,
2006). In particular, the neuroticism ⁄ anxiety trait is an important risk
factor for the development of depression (Ball & Schottenfeld, 1997;
Wang et al., 2002). Consequently, as a secondary aim of these studies,
we examined the relationship between CUS-induced electrophysiolog-
ical and behavioral changes and the anxiety trait of individual animals.
Anxiety trait was assigned on the basis of the behavior of each animal
observed during an elevated plus maze (EPM) task 1 week prior to the
start of the CUS procedure. In this case, we hypothesized that a greater
impact of the CUS on electrophysiological and behavioral measures
might be observed in animals deﬁned as having high trait anxiety.
Materials and methods
Subjects
Adult male Sprague-Dawley rats (Charles River Laboratories) were
used. Animals were housed individually and maintained under light-
and temperature-controlled conditions. Animal care procedures were
approved through a license issued by the Cantonal Veterinary Author-
ities (Vaud, Switzerland) and were consistent with GlaxoSmithKline’s
guidelines for the care and use of animals in research.
General experimental paradigm
At 2 weeks after arrival, rats were handled daily for 3 days. They were
then tested in the EPM to determine individual anxiety level.
Subsequently, rats were matched according to their body weight and
anxiety level, and randomly assigned to the different experimental
groups (two or four depending on the speciﬁc experiment). The CUS
protocol lasted 3 weeks, starting 1 week after the EPM. At 24 h after
the last CUS day, rats were anaesthetised with pentobarbital
(50 mg ⁄ kg i.p.) and either decapitated and brains removed for
amygdala electrophysiology or perfused in 4% paraformaldehyde in
0.1 m phosphate buffer for immunohistochemistry procedures.
Behavioral indexes of the impact of CUS were evaluated through
responses obtained during the CUS: (i) contextual fear conditioning on
days 20 and 21; and (ii) a forced swimming test on days 7 and 14.
EPM
Anxiety-related behaviors were evaluated using the EPM test (Herrero
et al., 2006). Brieﬂy, the test consists of two opposing open arms
(45 · 10 cm) and two enclosed arms (45 · 10 · 50 cm) that extend
from a central platform (10 · 10 cm), elevated 65 cm above the ﬂoor.
The rats were placed individually on the central platform and allowed
to explore the maze for 5 min. Behavior was monitored using a video
camera and analysed with a computerized tracking system (Ethovision
3.1.16, Noldus IT, The Netherlands). Time spent in the open and
closed arms (and their edges) was recorded. Subsequently, and for
each experiment, rats were classiﬁed according to the time they spent
in the open arms of the maze as high anxiety (HA) when values were
below the mean of the whole population of rats tested and low anxiety
(LA) when values were above the mean.
CUS
During the course of 3 weeks, rats were exposed daily to various
stressors that were applied at different times of the day and included:
bright light (300 lx, 30 min), elevated platform (2 h), predator odor
(1 h exposure to 10 lL of trimethylthiazoline, a synthetic compound
originally isolated from fox feces), contextual fear conditioning (three
1 s shocks of 0.4 mA) followed by a subsequent test session (exposure
to context associated with shocks, see below for more detailed
methods), acoustic stimulation (78–115 dB noise bursts), forced swim
test in tanks of different sizes (see below for detailed methods),
exposure to a novel arena, and an EPM (similar to that described
above to assess anxiety trait).
Contextual fear conditioning
Rats were trained using three 1 s footshocks of 0.4 mA intensity in a
rodent observation cage on day 20 and tested by being placed into the
same chamber for 5 min in the absence of shocks on day 21. Freezing
behavior during the test session was captured by a video camera and
was deﬁned as behavioral immobility except for movement needed for
respiration. Video recordings were analysed blind to treatment with
the assistance of a computer program (The Observer 5.0.25, Noldus
IT, 2003). For comparison, a group of naive, undisturbed rats was
trained in the same contextual fear conditioning procedure to provide a
control.
Forced swimming test
Rats were submitted to two 10 min forced swim sessions on days 7 and
14. Rats were individually placed in a plastic beaker (25 cm diameter,
46 cm deep) containing 30 cm of water (25 ± 1C) for 10 min.
Behavior was recordedwith a video camera and the time spent immobile
(making only those movements necessary to keep the nose above the
water), swimming, climbing and diving was recorded manually using a
computer program (The Observer 5.0.25, Noldus IT, 2003).
Electrophysiological studies
In-vitro brain slices were obtained 24 h after rats were submitted to the
last CUS session. One control and one stressed rat were studied on
each day in an experimenter-blind manner and one to three amygdala
slices were examined for each animal. Rats were anesthetized with
pentobarbital (50 mg ⁄ kg i.p.) and decapitated. The brain was removed
and cooled rapidly in a modiﬁed artiﬁcial cerebrospinal ﬂuid solution
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(0–6C) bubbled continuously with 95% O2 and 5% CO2 to maintain
physiological pH (7.35–7.45). Slices (400 lm) were cut in the
horizontal orientation on a Vibroslice (Campden Instruments) and
transferred to a holding chamber containing artiﬁcial cerebrospinal
ﬂuid at room temperature 22 ± 1C. After at least 1 h, a slice was
transferred to the recording chamber, where it was fully submerged
and continuously perfused with oxygenated artiﬁcial cerebrospinal
ﬂuid maintained at 33 ± 1C.
Glass microelectrodes containing 154 mm NaCl (resistance
3–8 MW) were placed within the BLA visually and then adjusted
to record the best ﬁeld potential. Extracellular ﬁeld potentials were
evoked by electrical stimulation delivered to the lateral nucleus of
the amygdala (0.05 Hz, 0.1 ms duration) with a bipolar electrode.
The potentials were ampliﬁed (Axoprobe-1A, Axon Instruments)
and acquired using a National Instruments interface and custom
software. A stimulation current sufﬁcient to evoke a response that
was 50–60% of the maximum was used unless otherwise indicated.
Drugs were applied by bath perfusion in the artiﬁcial cerebrospinal
ﬂuid and introduced to the recording chamber at a ﬂow rate of
2 mL ⁄min. The amplitude of the second negative-going fPSP of
evoked BLA ﬁeld potentials was measured as described by Ugolini
et al. (2008).
Drugs
The CRFR1 antagonist NBI30775 was a gift from Neurocrine Inc. It
was administered subcutaneously at 10 mg ⁄ kg in 4% v ⁄ v dimethyl-
sulfoxide ⁄ 0.5% w ⁄ v methocell, 1 h before the application of the
stressor on each day of the CUS or at the corresponding time in the
non-stressed control group. Vehicle was administered in a similar
manner to stressed and non-stressed groups. For the electrophysio-
logical experiments, human ⁄ rat CRF was used (Sigma-Aldrich,
St Louis, MO, USA).
Immunohistochemistry
Ki67 and CRFR1 immunohistochemistry
Tissue was processed ‘free-ﬂoating’ for immunohistochemistry. After
washing, sections were incubated with 10% methanol and 3% H2O2
in phosphate-buffered saline (PBS) for 10 min to block endogenous
peroxidase activity. They were then treated for 1 h with 5% normal
donkey serum (Jackson Laboratories) in PBS with 0.2% Triton-
X100 (Sigma) and incubated overnight at room temperature in either
mouse monoclonal IgG anti-Ki67 (1 : 200, Novocastra) or goat
polyclonal IgG anti-CRFR1 (1 : 5000, Santa Cruz). After washing,
sections were incubated for 30 min with donkey anti-mouse or
donkey anti-goat IgG biotinylated antibodies (Jackson Laboratories,
1 : 250) followed by an avidin-biotin-peroxidase complex (ABC,
Vector Laboratories) for 30 min in PBS. Color development was
achieved by incubating with 3,3¢-diaminobenzidine tetrahydrochlo-
ride (Sigma) for 4 min. PBS containing 0.2% Triton-X100 and 3%
normal donkey serum (NDS) was used for primary and secondary
antibody dilution. All sections passed through all procedures
simultaneously to minimize any variability arising from immuno-
histochemical procedures. The number of Ki67-expressing cells in
the 100% dentate gyrus was estimated using a modiﬁed version of
the fractionator method (West, 1993). Cell somata were identiﬁed
and counted with a 40· objective. Cells appearing in the upper focal
plane were omitted to prevent counting cell caps. The volume of
areas analysed was determined for each animal using Cavalieri’s
principle (Gundersen & Jensen, 1987).
Double immunoﬂuorescence
Double immunohistochemistry using anti-CRFR1 antibody and anti-
bodies against neuronal nuclear protein (NeuN) and Ki67 was
performed to assess whether the CRFR1 was expressed in newly
generated or mature neurons. In general, sections were processed as
described above but the endogenous peroxidase block was omitted.
The sections were incubated overnight with goat polyclonal IgG anti-
CRFR1 (Santa Cruz, 1 : 5000, sc-1757) and one of the following
primary antibodies: mouse monoclonal anti-NeuN (1 : 200, Chem-
icon) or mouse monoclonal anti-Ki67 (1 : 200, Novocastra). After
washing, sections were incubated with donkey anti-goat IgG and
donkey anti-mouse IgG secondary antibodies conjugated with Alexa
488 or Alexa 555 (Molecular Probes, 1 : 200) in PBS containing 0.2%
Triton X-100 and 3% NDS. All sections were observed under a
confocal microscope (Leica TCS-SP2). Z-series of optical sections
(1 lm apart) were obtained using sequential scanning mode. These
stacks were processed with LSM 5 Image Browser software. NeuN-
and Ki67-immunoreactive cells were ﬁrst identiﬁed using conven-
tional ﬂuorescence microscopy. A stack of confocal images covering
all of its three-dimensional extension was then taken to conﬁrm the
labelling for the CRFR1 antibody. Fifty immunoreactive cells for each
marker were analysed.
In-situ hybridization
Riboprobes speciﬁc for the rat CRF and CRFR1 mRNA were used.
Before hybridization, labeled probe was added to the hybridization
cocktail. After hybridization, slides were air dried and exposed to Fuji
Imaging plates (BAS-TR 2025) together with 14C standards. Semi-
quantitative analyses were performed on the in-situ hybridization
images. Light transmittance values were measured from the digitalized
images using an image analysis software system (ais 4.0, Imaging
Research, St Catharines, Canada). Based on the known radioactivity of
the standards relative to their transmittance levels, the light transmit-
tance values phospho-stimulated luminescence (PLS) per mm2 were
converted to nCi ⁄ g using a calibration curve. The regions of interest
were deﬁned by anatomical landmarks in conjunction with a rat brain
atlas (Paxinos & Watson, 1998). For each animal, two consecutive
sections were considered and the regions were analysed bilaterally.
The measurements of each speciﬁc brain region were taken by
individually tracing the structures on the TV monitor with a cursor.
Statistics
Data (except for correlational analyses) are expressed as mean ±
SEM. Statistical analyses of data included Student’s t-test for paired or
unpaired samples, as appropriate, anova (one-way, factorial and ⁄ or
repeated measures, as appropriate), followed by Fisher’s Protected least
signiﬁcant difference (PLSD) post-hoc tests and Pearson’s correlation.
Results
The impact of chronic stress on the effect of CRF on ex-vivo
electrophysiological responses in the BLA and on stress-related
behaviors – correlations with trait anxiety
In a ﬁrst experiment, ﬁve control rats and ﬁve rats submitted to CUS
were studied. The impact of the CUS procedure was determined by
examining body weight gain during the 3 weeks of stress exposure. As
expected, animals submitted to CUS showed a signiﬁcant reduction in
body weight gain (% Gain: Control group: 1st week, 133.46 ± 1.92;
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2nd week, 143.73 ± 2.28; 3rd week, 150.34 ± 2.47; CUS group: 1st
week, 124.28 ± 1.54; 2nd week, 134.33 ± 1.60; 3rd week,
138.62 ± 1.76%; repeated measures anova: F1,8 = 14.04, P < 0.006).
In slices from control rats, stimulation of the lateral amygdala
evoked a short latency (1 ms) negative-going ﬁeld potential in the
BLA (Fig. 1A), which is presumed to reﬂect a pre-synaptic ﬁbre
volley and ⁄ or direct activation of neurons within the BLA (Isoardi
et al., 2004), and which could be inhibited by tetrodotoxin (100 nm;
data not shown). This was followed by a second, longer latency (2–
3 ms) negative-going fPSP that could be inhibited by application
of the a-amino-3-hydroxy-5-methylisoxazole-4-propionate ⁄ kainate
receptor antagonist, 6-cyano-7-nitroquinoxaline-2,3-dione (10 lm,
Fig. 1A), and is presumed to reﬂect the post-synaptic response of
predominantly pyramidal neurons in the BLA (Isoardi et al., 2004).
Application of CRF (0.1 lm) to slices (n = 7) obtained from
unstressed, control rats enhanced the amplitude of the longer latency
synaptic response by 23 ± 4% but had no effect on the early response
(Fig. 1B). However, in slices (n = 7) from rats submitted to CUS, the
enhancement of the fPSP amplitude by CRF was signiﬁcantly smaller
(7 ± 4%, t = 3.01, d.f. = 12, P < 0.05; Fig. 1B).
Analysis of the current-response relationship in the absence and
presence of CRF showed that, in non-stressed control rats, the peptide
increased the amplitude of the fPSP over a range of stimulus
intensities (repeated measures anova: main effect of CRF,
Fig. 1. Impact of chronic stress on the effect of CRF on ex-vivo electrophysiological responses in the BLA and correlations with trait anxiety. (A) A characteristic
ﬁeld response recorded in the BLA following stimulation of the lateral amygdala in normal artiﬁcial cerebrospinal ﬂuid (aCSF) (a) and in the presence of 6-cyano-
7-nitroquinoxaline-2,3-dione (CNQX) (10 lm) (b). A short-latency negative-going ﬁeld potential is followed by a second, longer latency, negative-going potential
(fPSP). The second component of the response is blocked completely by the a-amino-3-hydroxy-5-methylisoxazole-4-propionate ⁄ kainate receptor antagonist,
CNQX. All results refer to this component, whose amplitude was measured as shown by the dotted lines. (B) Histogram showing the effect of CRF (0.1 lm) on the
amplitude of fPSPs evoked in control slices or slices taken from rats submitted to CUS. Current-response relationship for evoked fPSPs in the absence ( ¯¯) and
presence (?) of CRF (0.1 lm) in slices taken from (C) control rats and (D) stressed rats. Results are the mean ± SEM from seven slices from ﬁve rats in each group.
(E) Positive correlation between an anxiety measure (percent time spent in the open arms of the EPM during the pre-stress testing) and the percent CRF-induced
increase in fPSP amplitude in animal submitted to CUS. (F) Similar correlation as in E, this time between the percent time spent at the edge of the open arms and the
percent CRF-induced increase in fPSP amplitude in animals submitted to CUS. *P < 0.05.
Stress, amygdala responsiveness and CRF 1839
ª The Authors (2008). Journal Compilation ª Federation of European Neuroscience Societies and Blackwell Publishing Ltd
European Journal of Neuroscience, 28, 1836–1848
F1,72 = 8.1, P < 0.015; main effect of current, F6,72 = 138.0,
P < 0.0001; interaction between current and CRF, F6,72 = 2.65,
P < 0.02; Fig. 1C) but this was not the case in stressed rats [repeated
measures anova: main effect of current, F6,72 = 85.0, P < 0.0001; no
effect of CRF, F1,72 = 0.36, not signiﬁcant (n.s.); no interaction
between current and CRF, F6,72 = 0.63, n.s.; Fig. 1D].
We hypothesized that anxiety trait would modulate the impact of
chronic stress. In particular, we evaluated whether anxiety trait
(determined from a baseline EPM conducted 1 week before CUS)
might predict the degree of effect of CRF on electrophysiological
responses in the BLA. No correlation was observed between EPM
measures and electrophysiological response to CRF in control rats
(n.s.; data not shown). However, in chronically stressed animals, the
time spent in the open arms (r = 0.92, P < 0.03; Fig.1E) and the time
spent near the edge of the open arms (r = 0.98, P < 0.003; Fig. 1F)
during the EPM test were signiﬁcantly correlated with the subsequent
effect of CRF on fPSP amplitude in the BLA; the higher the trait
anxiety, the lower the facilitation of fPSP responses by CRF.
At the behavioral level, the ability of CUS to produce emotional
and ⁄ or learning alterations was veriﬁed by assessment of behavioral
changes in two tests performed as part of the CUS procedure: contextual
fear conditioning (days 20 and 21) and forced swimming test (days 7
and 14). In agreement with previous reports (Sandi et al., 2001; Cordero
et al., 2003), chronically stressed rats (n = 5) froze signiﬁcantly more
than a group of naive control rats (n = 6) during the test session
(t = 2.4, d.f. = 9, P < 0.04; Fig. 2A), indicative of a stress-induced
enhancement of conditioned fear. This effect cannot be attributed to an
altered sensitivity to the shock in the stress group as post-shock freezing
during the training session did not differ between the two groups
(t = 0.66, d.f. = 9, n.s.). We further determined whether there might be
a correlation between the degree of freezing observed during the 24 h
test session in the stress group and the percent increase in fPSP
amplitude recorded following CRF stimulation in vitro; however, a
Pearson test failed to show a signiﬁcant correlation (r = )0.53,
P = 0.36; Fig. 2B). Behavior in the forced swim test performed on
days 7 and 14 of the CUS was also analysed. A signiﬁcant increase
was observed in the percentage of time spent ﬂoating on day 14
(72.34 ± 4.68%) compared with day 7 (50.92 ± 2.03%) (t-test paired
samples: t = 4.10, d.f. = 4, P < 0.015), with the increase particularly
evident over the ﬁrst 5 min of the test (t = 3.49, d.f. = 4, P < 0.025;
Fig. 2C). Moreover, a signiﬁcant correlation was found between the
percent increase in immobilization from day 7 to day 14 and the percent
increase in fPSP amplitude following CRF stimulation in vitro
(r = )0.878, P < 0.05; Fig. 2D).
Fig. 2. Impact of CUS on stress-related behaviors. (A) Contextual fear conditioning performed on days 20 and 21 of the CUS; stressed animals spent more time
freezing during the retention test (Test 24 h) than controls. (B) Lack of signiﬁcant correlation between the percent freezing during the 24 h test and the percent
increase in fPSP amplitude in the BLA following CRF stimulation. (C) Forced swimming test (FS) performed on days 7 and 14 of the CUS; in stressed animals, an
increase in the percent time ﬂoating during FS was increased from the ﬁrst (day 7) to the second (day 14) exposure. (D) Signiﬁcant negative correlation between the
percent increase in immobilization displayed by animals in the FS on day 14 as compared with day 7. Results in A and C are the mean ± SEM. *P < 0.05 vs. control;
**P < 0.01 vs. FS day 7.
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The impact of chronic stress on amygdaloid CRF systems
according to anxiety trait
Given that the impact of CUS on the electrophysiological response to
CRF in the BLA was correlated with trait anxiety, we ran a second
experiment to examine the effects of CUS on endogenous levels of
CRFR1 and CRF peptide in the amygdala in rats classiﬁed as HA and
LA.
Rats (n = 24) were ﬁrst classiﬁed according to their behavior in the
EPM as either HA (n = 14; open arms, 2.72 ± 0.84%) or LA (n = 10;
open arms, 18.31 ± 2.70%). Pairs of rats within each anxiety group
were then matched and equally distributed into the control (HA, n = 7;
LA, n = 5) and stress (HA, n = 7; LA, n = 5) groups. Once again, the
CUS procedure resulted in reduced body weight gain compared with
unstressed rats (% Gain: Control group: 1st week, 111.61 ± 0.70; 2nd
week, 118.85 ± 1.16; 3rd week, 124.39 ± 1.20; CUS group: 1st week,
124.28 ± 1.54; 2nd week, 114.24 ± 1.48; 3rd week, 122.29 ± 1.10%).
A two-way repeated measures anova found a main effect of stress
(F1,20 = 4.83, P < 0.04) and a trend towards a main effect of anxiety
trait (F1,20 = 3.49, P = 0.076) on body weight gain.
In order to compare the impact of CUS on amygdala CRFR1
mRNA between HA and LA groups, a two-way repeated measures
anova was performed with anxiety trait and stress as between-subject
factors, and amygdala nucleus as a within-subject factor. No
signiﬁcant main effect of anxiety trait or stress was observed (Stress:
F1,20 = 1.22, n.s.; Anxiety trait: F1,20 = 0.16, n.s.). There were also no
signiﬁcant interactions between either anxiety trait or stress and
amygdala nucleus, or between all three factors (Stress · Anxi-
ety · Amygdala: F2,40 = 0.76, n.s.). However, a signiﬁcant interaction
between stress and anxiety trait was found (F1,20 = 4.56, P < 0.045).
Post-hoc analyses revealed that, in the absence of stress, there was a
trend for HA rats to show higher expression of CRFR1 mRNA in the
amygdala nuclei analysed compared with LA rats (P < 0.088).
However, stress signiﬁcantly reduced the expression of CRFR1
mRNA in the amygdala of HA rats (P < 0.021). This reduction was
not observed in LA rats. As might be expected, there was also a
signiﬁcant main effect of amygdala nucleus (F2,40 = 19.55,
P < 0.001). Therefore, further analyses were performed for each
nucleus. Although no signiﬁcant main effect of any of the factors was
observed, signiﬁcant interactions between anxiety trait and stress were
found in the CeA (F1,20 = 7.77, P < 0.011) and medial nucleus of the
amygdala (F1,20 = 4.93, P < 0.038). Post-hoc analyses conﬁrmed that
CRFR1 mRNA expression in non-stressed rats differed according to
trait anxiety, with HA rats showing higher levels of expression than
LA rats (CeA, P < 0.04; medial nucleus of the amygdala, P = 0.06).
Post-hoc analyses also showed that stress was associated with a
signiﬁcant reduction in CRFR1 mRNA expression in HA rats (control
vs. stress: CeA, P < 0.008; medial nucleus of the amygdala,
P < 0.033) but not LA rats.
Analysis of the expression of CRF peptide mRNA in the CeA
(Fig. 3B) indicated a lack of effect of stress (F1,20 = 2.75, n.s.) or
anxiety trait (F1,20 = 2.55, n.s.) and no interaction between these
factors (F1,20 = 0.45, n.s.).
Effects of the CRFR1 antagonist NBI30775 on the
electrophysiological impact of chronic stress
In a further experiment, we evaluated whether daily administration of
the selective, non-peptide CRFR1 antagonist NBI30775 before each
daily stressor would prevent stress-induced alterations in: (i) the effect
of CRF on fPSP amplitude in the BLA, (ii) stress-related behaviors
and (iii) hippocampal cell proliferation. As in previous experiments,
analysis of body weight was conducted, in this case using three-way
repeated measures anova with anxiety trait, stress and drug as
between-subject factors, and time as a within-subject factor [% Gain:
Control + Vehicle group (n = 18): 1st week, 104.61 ± 0.34; 2nd
week, 109.24 ± 0.49; 3rd week, 112.49 ± 0.55; Control + NBI30775
group (n = 19): 1st week, 104.05 ± 0.74; 2nd week, 108.14 ± 0.77;
3rd week, 111.31 ± 0.90; CUS + Vehicle group (n = 20): 1st week,
102.76 ± 0.34; 2nd week, 103.68 ± 1.07; 3rd week, 108.35 ± 0.75;
CUS + NBI30775 group (n = 20): 1st week, 104.47 ± 1.26; 2nd
week, 106.77 ± 1.43; 3rd week, 110.08 ± 1.56]. Signiﬁcant main
effects were found for stress (F1,69 = 6.79, P < 0.011) and time
(F2,138 = 257.66, P < 0.001). No signiﬁcant effects of anxiety trait or
drug were observed and there were no signiﬁcant interactions between
the factors.
At the end of the CUS procedure, approximately half of the animals
from each experimental condition were used for electrophysiological
and behavioral analyses, whereas the other half were prepared for
evaluation of hippocampal cell proliferation.
Electrophysiology experiments were conducted to determine the
effect of CRF on evoked fPSPs in the BLA 24 h after the ﬁnal CUS
challenge. Analysis of the percent increase in fPSP amplitude
produced by CRF (0.1 lm) was conducted using a two-way anova
with stress and drug as between-subject factors. Consistent with the
ﬁrst experiment described above, a signiﬁcant effect of stress was
Fig. 3. Impact of CUS on amygdaloid CRF systems according to anxiety
trait. In-situ hybridization experiments indicated a stress-induced downregu-
lation of CRFR1 mRNA in the amygdala in (A) HA but not (B) LA rats. No
evidence of a modulation of CRF mRNA in the CeA was observed in HA or
LA rats. MeA, medial nucleus of the amygdala. *P < 0.05 and **P < 0.01
vs. HA-Control.
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observed (F1,32 = 11.9, P < 0.002). There was no main effect of
NBI30775 (F1,32 = 0.16, n.s.); however, a signiﬁcant interaction
between stress and drug was observed (F1,32 = 10.3, P < 0.003;
Fig. 4A). Post-hoc analyses indicated that, consistent with the ﬁrst
experiment, the enhancement of fPSP amplitude in the BLA by CRF
was signiﬁcantly reduced by CUS (control + vehicle vs. stress + vehi-
cle, P < 0.001). NBI30775 prevented the reduction in response
induced by CUS; in the stress groups, NBI30775-treated rats showed a
higher percent increase in fPSP amplitude to CRF stimulation than
vehicle-treated rats (P < 0.05). Finally, in the non-stressed groups, the
increase in fPSP amplitude produced by CRF was reduced by
NBI30775 treatment compared with vehicle-injected rats (P < 0.02).
In a further analysis, the inﬂuence of anxiety trait on the
electrophysiological response to CRF was considered (Fig. 4B). A
three-way anova, with anxiety trait, stress and drug as between-
subject factors, showed once again a signiﬁcant main effect of stress
(F1,28 = 14.93, P < 0.001). A main effect of anxiety trait or drug was
not observed and neither was there a signiﬁcant interaction between
stress and anxiety trait. However, signiﬁcant interactions between
anxiety and drug (F1,28 = 6.02, P < 0.021), and between stress and
drug (F1,28 = 10.21, P < 0.003) were observed. No statistical differ-
ences were found for any other interactions; however, the subdivision
by anxiety trait resulted in quite low numbers of subjects in some
groups (n = 4–6). Post-hoc analyses conﬁrmed previous observations
indicating a correlation between the stress-induced reduction in
electrophysiological response to CRF and anxiety trait. Speciﬁcally,
HA rats that were not administered NBI30775 (i.e. HA-Stress-
Vehicle) showed the most dramatic reduction in electrophysiological
response to CRF (P < 0.001 vs. HA-Control-Vehicle), whereas a
smaller stress-induced reduction was observed in LA animals that did
not reach signiﬁcance when compared with LA-Control-Vehicle rats
(n.s.). As a result, a signiﬁcant effect of NBI30775 treatment was
observed only in HA animals: (i) in the absence of stress
the antagonist was associated with a signiﬁcant reduction in the
electrophysiological response to CRF (HA-Control-Vehicle vs. HA-
Control-NBI30775, P < 0.001); and (ii) in animals submitted to
CUS, the antagonist partially reversed the stress-induced decrease in
the CRF response, with animals in the HA-Stress-NBI30775 group
showing larger responses to CRF than rats in the HA-Stress-Vehicle
group (P < 0.05). Finally, a signiﬁcant difference was also found
within the vehicle-treated non-stressed rats (Control-Vehicle), with
post-hoc analyses indicating larger CRF responses in HA compared
with LA rats (P < 0.016).
Effects of the CRFR1 antagonist NBI30775 on the behavioral
impact of chronic stress
Time spent freezing during the two sessions of the fear conditioning
test, conducted on days 20 and 21 of the CUS, was analysed using a
repeated measures anova (vehicle, n = 10; NBI30775, n = 10) with
drug as a between-subject factor and session as a within-subject factor.
A signiﬁcant main effect of session (F1,18 = 14.87, P < 0.001) was
observed, consistent with acquisition of the conditioned response.
There was no signiﬁcant main effect of drug (F1,18 = 2.89, n.s.);
furthermore, there was no signiﬁcant interaction between drug and
session (F1,18 = 0.044, n.s.; Fig. 5A). In a further analysis that
included anxiety trait as a between-subject factor (Fig. 5B), a two-way
repeated measures anova conﬁrmed the signiﬁcant effect of session
(F1,16 = 13.75, P < 0.002) and a lack of a main effect of anxiety trait
(F1,16 = 0.35, n.s.); however, there was a trend towards a signiﬁcant
effect of drug (F1,16 = 3.02, P = 0.10) and for an interaction between
anxiety trait and drug (F1,16 = 2.44, P = 0.13) but not for other
potential interactions (all n.s.). The tendency towards signiﬁcance of
an anxiety trait by drug interaction reﬂects signiﬁcantly less freezing
during the training and testing sessions of the HA rats treated with
NBI30775 (P < 0.02), which was not observed in LA animals (n.s.),
as indicated by a separate anova and post-hoc analyses for each
group classiﬁed according to anxiety trait.
Time spent ﬂoating during the ﬁrst 5 min of testing in the forced
swimming test on days 7 and 14 was analysed using a two-way
repeated measures anova with drug as a between-subject factor and
day (7 or 14) as a within-subject factor. Signiﬁcant main effects of
drug (F1,18 = 4.87, P < 0.04) and day (F1,18 = 396.47, P < 0.0001)
were observed but no signiﬁcant interaction was observed between
them (F1,18 = 0.04, n.s.; Fig. 5C). Thus, NBI30775 signiﬁcantly
reduced the percent time spent ﬂoating across both test days.
Student’s t-tests for each session indicated a tendency for NBI30775
to reduce ﬂoating time on day 7 (P = 0.06) and a signiﬁcant effect
on day 14 (P < 0.04). When a further analysis was conducted,
taking into account anxiety trait (Fig. 5D), a two-way repeated
measures anova, with anxiety trait included as a between-subject
Fig. 4. Effects of the CRFR1 antagonist NBI30775 on the electrophysiological responses to ex-vivo CRF stimulation in the BLA in control and stressed rats. (A)
Effect of CRF on the amplitude of fPSPs evoked in slices taken from Control-Vehicle and Control-NBI30775-treated rats, and from Stress-Vehicle and Stress-
NBI30775-treated rats. Stressed animals injected with vehicle showed a reduction in the fPSP amplitude. Although to a lesser extent, NBI30775 treatment also
reduced the enhancement of fPSPs by CRF. Moreover, NBI30775 partially reduced the magnitude of the stress-induced decrease of the fPSP amplitude to CRF
stimulation. (B) When data were split according to the animals’ pre-stress anxiety levels, HA animals showed both the reported downregulation by CUS in fPSP
amplitude and a reduction in this response in animals treated with the antagonist (both control and stressed) as compared with the Control-Vehicle group. In HA rats,
the antagonist partially reversed the stress-induced downregulation in fPSP amplitude. No signiﬁcant effects of either CUS or NBI30775 were observed in LA rats
but control LA rats showed lower fPSP amplitude than control HA rats (i.e. Control-Vehicle). *P < 0.05 and **P < 0.01 vs. Control-Vehicle; #P < 0.05 vs. Stress-
Vehicle; +P < 0.05 and ++P < 0.01 vs. HA-Control-Vehicle; $P < 0.05 vs. HA-Stress-Vehicle.
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factor, signiﬁcant main effects of drug (F1,16 = 4.665, P < 0.046)
and day (F1,16 = 369.71, P < 0.001) were conﬁrmed but no main
effect of anxiety trait was observed (F1,16 = 0.02, n.s.) or an
interaction between any of the factors (all n.s.). When each session
was analysed separately, a signiﬁcant effect was revealed between
LA-Vehicle and LA-NBI30775 groups for each testing day (both
P < 0.05).
In the remaining half of the animals from this experiment (n = 8–10
rats per group), we examined the impact of CUS and NBI30775 on
cell proliferation in the dentate gyrus of the hippocampus. The number
of Ki67-immunoreactive cells in sections of the dentate gyrus was
analysed using a two-way anova with stress and drug as between-
subject factors. A signiﬁcant main effect of both stress (F1,35 = 4.224,
P < 0.047) and drug (F1,35 = 4.98, P < 0.033) was observed but no
interaction between them (F1,35 = 1.45, n.s.). Thus, stress was
associated with a reduction and NBI30775 was associated with an
increase in cell proliferation (Fig. 6A). Post-hoc analyses indicated
that cell proliferation for the control + NBI30775 group was signi-
ﬁcantly higher than for each of the other groups (P < 0.05). Examples
of the immunohistochemical labeling under the different experimental
conditions are shown in Fig. 7. Double-labeling experiments showed
coincidental labeling for CRFR1 and NeuN (Fig. 7) but not for
CRFR1 and the proliferation marker Ki67 (Fig. 7), indicating a
localization of the CRFR1 in mature, but not new, hippocampal
neurons.
In a subsequent three-way anova, anxiety trait was included as a
between-subject factor (Fig. 6B). Signiﬁcant main effects of stress
(F1,27 = 6.96, P < 0.014) and drug (F1,27 = 5.21, P < 0.031) were
conﬁrmed but there was no signiﬁcant main effect of anxiety trait
(F1,27 = 0.10, n.s.). However, signiﬁcant interactions between anxiety
trait and stress (F1,27 = 8.69, P < 007) and between anxiety trait and
drug (F1,27 = 7.41, P < 011) were observed. None of the other
potential interactions were signiﬁcant. Post-hoc analyses indicated
that: (i) in vehicle-treated animals, the CUS procedure induced a
signiﬁcant reduction in cell proliferation in HA rats (compared with
unstressed HA rats, P < 0.05) that was not observed in LA rats
(stressed vs. control LA animals, n.s.); and (ii) in the absence of stress,
NBI30775 increased cell proliferation only in HA rats (compared with
vehicle-treated HA animals, P < 0.01), having no effect on prolifer-
ation in LA rats (drug-treated vs. vehicle-treated LA animals, n.s.).
Furthermore, cell proliferation in HA and LA rats differed signiﬁ-
cantly, with HA rats showing greater proliferation than LA rats
(P < 0.01). A subsequent two-way anova, with stress and drug as
between-subject factors, performed on the proliferation results from
animals with each anxiety trait separately, indicated a lack of effect of
either stress or drug on hippocampal cell proliferation among the LA
animals. However, signiﬁcant main effects of stress (F1,13 = 14.46,
P < 0.003) and drug (F1,13 = 11.60, P < 0.005) were observed among
the HA rats, although once again there was no interaction between the
two factors (F1,13 = 0.68, n.s.). Thus, this analysis suggests that the
Fig. 5. Effects of the CRFR1 antagonist NBI30775 on the behavioral impact of chronic stress. (A) The contextual fear conditioning test performed on days 20 and
21 did not reveal an effect for NBI30775 treatment when all animals were considered. (B) However, in HA animals, NBI30775 treatment reduced the freezing
responses displayed in these chronically stressed rats, whereas it had no effect on LA rats. (C) Histogram showing percent time ﬂoating during the ﬁrst 5 min of the
forced swimming tests (FSs) delivered on days 7 and 14 of the CUS. NBI30775 treatment reduced the percent time that rats ﬂoated. (D) When animals were split
according to anxiety levels, the antagonist was effective in reducing ﬂoating levels in LA rats. *P < 0.05 vs. Vehicle group same session; +P < 0.05 vs.
corresponding Vehicle group same anxiety level.
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previous ﬁnding regarding the negative and positive effects of stress
and NBI30775 on cell proliferation, respectively (P < 0.05 in each
case), is particular to HA rats (Fig. 6B).
Discussion
In the present study, our goal was to evaluate whether chronic stress
might alter the BLA electrophysiological response to CRF and
whether this might be inﬂuenced by the animals’ anxiety trait. We also
set out to determine whether a CRFR1 antagonist, given during the
CUS procedure, might prevent the effects of stress on electrophy-
siological responses. Using a 3 week CUS protocol, we show here
that the potentiating effect of CRF on evoked fPSPs in the BLA is
signiﬁcantly reduced in chronically stressed rats. This reduction is
accompanied by behavioral changes that validate the chronic stress
procedure; stressed animals showed enhanced contextual fear condi-
tioning, as previously shown for other chronic stress protocols (Sandi
et al., 2001; Cordero et al., 2003), and increased depression-like
behavior (immobility in the forced swimming test) over the course of
the CUS procedure. Moreover, the percent increase in immobilization
across the CUS procedure correlated with the inhibition of the
potentiating effect of CRF on evoked fPSPs in the BLA induced by
stress, i.e. the higher the percent increase in immobilization, the lower
the percent increase in fPSP amplitude. Our results reinforce the view
that chronic stress reduces sensitivity to CRF, as suggested by recent
work in which chronic stress attenuated behavioral responses induced
by intracerebroventricular administration of CRF and induced
depression-like behavior in the forced swim test (Swiergiel et al.,
2008).
Interestingly, we also found that the degree of reduction of CRF-
induced facilitation of fPSP was dependent upon the animals’ trait
anxiety, with the reduction in the enhancing effect of CRF being
particularly evident in highly anxious rats. These results suggest a
vulnerability of high trait anxiety individuals to develop alterations in
amygdaloid CRF systems under exposure to chronic stress. These
results ﬁt with a growing body of data indicating that high trait anxiety
is a vulnerability factor for diverse psychiatric alterations due to stress
and may be especially relevant in patients with generalized anxiety
disorder or major depression (Chambers et al., 2004).
Emotional responses are well known to be regulated by the
amygdala, where stress has been repeatedly shown to induce CRF
release (Koob & Heinrichs, 1999), which is followed by subsequent
activation of CRFRs and which leads to alterations in emotional
behavior (Dunn & Berridge, 1990; Lee & Davis, 1997; Sajdyk &
Gehlert, 2000). In vivo, CRF is released in the BLA by afferents from
the CeA (Swanson et al., 1983; Roozendaal et al., 2002). Cumulative
evidence indicates that activation of CRFR1 in the BLA is critical for
attributing emotional salience to potentially anxiogenic or aversive
stimuli (Sajdyk et al., 1999; Roozendaal et al., 2002; Shekhar et al.,
2005) and appears to be essential for the consolidation of emotional
memories (Pare´ et al., 2004). Stress-induced plasticity within the BLA
has been proposed as a critical step in the development of chronic
anxiety-related disorders (Rainnie et al., 2004; Shekhar et al., 2005).
Several studies of depressed humans have observed hyperactivation of
the amygdala at rest or in response to an emotional stimulus (Drevets,
2000; Sheline et al., 2001; Siegle et al., 2002, 2007). The amygdala
response to emotional stimuli in these patients was found to predict the
outcome of antidepressant treatment, with evidence suggesting that
greater amygdala activation to emotional stimuli is associated with
greater symptom improvement 8 months later (Canli et al., 2005).
Furthermore, in depressed patients, behavioral, cognitive and auto-
nomic studies indicate that those patients that are more reactive to
emotional stimuli exhibit greater symptomatic improvement than do
individuals who show little emotional reactivity (Kasch et al., 2002;
Rottenberg et al., 2002). In the present study, rats characterized as
highly anxious were those that showed the smallest response to CRF
in the BLA following exposure to chronic stress. Therefore, we can
speculate that the reduction in amygdala response to CRF caused by
chronic stress might underlie the clinical observation of the relation-
ship between emotional reactivity and treatment outcome in depressed
patients. Furthermore, our results suggest that high trait anxiety might
predispose patients to a poorer prognosis. Although, to our know-
ledge, the inﬂuence of anxiety trait on treatment outcomes has not
been investigated in depressed patients, patients with Parkinson’s
disease with HA show evidence for reduced amygdala response to
emotional stimuli, inferred from a blunted startle response to aversive
pictures (Bowers et al., 2006).
With the exception of a study conducted with the CRFR1
antagonist, NB130775 (Zobel et al., 2000), there has been no clinical
evaluation of the efﬁcacy of this class of drug in patients with
depression. However, the present results provide a strong motivation
to do this. The results show that treatment with NBI30775 during
exposure to CUS prevented both the electrophysiological and
Fig. 6. Effects of the CRFR1 antagonist NBI30775 and chronic stress on hippocampal cell proliferation. Number of Ki67-immunoreactive (IR) cells in the dentate
gyrus of the hippocampus after CUS. (A) The CRFR1 antagonist NBI30775 increased cell proliferation in Control-Vehicle animals. (B) When animals were split
according to their anxiety levels, in HA rats, CUS decreased the number of newly generated cells and treatment with NBI30775 prevented the reduction. In HA rats,
NBI30775 substantially increased cell proliferation in control, unstressed rats. In rats previously characterized as LA, no effect of the drug or stress was observed but
LA rats submitted to stress (vehicle) showed higher proliferation levels than HA stressed (vehicle) rats and control unstressed rats injected with the antagonist had
lower proliferation levels than HA control unstressed rats. *P < 0.05 vs. all other groups; +P < 0.01 vs. HA-Stress-Vehicle; #P < 0.05 vs. HA-Stress-Vehicle;
$P < 0.01 vs. HA-Control-NBI307775.
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behavioral alterations induced by stress. Furthermore, when consid-
ering the animals’ trait anxiety, treatment with NBI30775 had the most
marked effect on HA rats, with less effect in the LA animals (although
they were more sensitive to the drug in the forced swimming test),
although of course the LA rats were less affected by the CUS in the
ﬁrst place. Furthermore, the electrophysiological response to CRF of
unstressed HA controls was approximately double the response
observed in LA controls. Thus, we can speculate that highly anxious
animals are characterized by a strong inﬂuence of CRF on excitability
of the BLA but this inﬂuence is particularly susceptible to reduction
by stress. However, treatment with a CRFR1 antagonist may
normalize the inﬂuence of CRF in highly anxious animals and render
them more resistant to the effects of stress. Consistent with the
electrophysiological ﬁndings, NBI30775 treatment also had a selective
effect on the freezing response of HA but not LA animals in the fear
conditioning task. In addition, NBI30775 prevented stress-induced
reductions in hippocampal cell proliferation, an effect that was again
observed in HA but not LA animals. In contrast, the ability of
NBI30775 to reduce immobility in the forced swim test was observed
in the whole sample and, particularly, in LA animals. Based on these
ﬁndings, we can speculate that CRFR1 antagonists might be
particularly effective in high trait anxiety patients who may be less
receptive to existing treatments; however, given the behavioral
ﬁndings it remains to be seen whether this will be the case for
Fig. 7. Microphotographs showing changes in CRFR1 expression in the granule cell layer of the dentate gyrus following CUS and ⁄ or treatment with CRFR1
antagonist (A–D). Characterisation of the phenotype of CRFR1-immunoreactive cells in the dentate gyrus: (E) Neurons positive for Neun (E1, Green) express
CRFR1 (E2, red). (F) Newly generated cells positive for ki67 (F1, green) are devoid of CRFR1 expression (F2, red). E3 and F3 show overlays.
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patients with depression as well as for patients with anxiety disorders,
such as post-traumatic stress disorder.
Several studies have shown that stress inhibits adult hippocampal
neurogenesis, a phenomenon that is suggested to be related to
depression (Duman, 2004; but see Sahay & Hen, 2007). Our results
indicate a particular vulnerability of high trait anxiety animals to show
diminished cell proliferation in the dentate gyrus following chronic
stress, which ﬁts with recent rodent studies suggestive of reduced adult
hippocampal neurogenesis associated with inhibited emotionality
(Earnheart et al., 2007; Leal-Galicia et al., 2007). We also show that
the chronic stress-induced reduction in cell proliferation is reversed by
chronic treatment with the CRFR1 antagonist, in agreement with a
previous study in mice employing another CRFR1 antagonist (Alonso
et al., 2004). Moreover, in highly anxious non-stressed animals,
NBI30775 increased cell proliferation. Therefore, our results support
the view that antagonizing CRFR1 has a similar effect to other classes
of antidepressant drugs reported to increase both cell proliferation and
neurogenesis in the dentate gyrus of the adult hippocampus following
chronic treatment (Malberg & Blendy, 2005); however, the beneﬁcial
effects of CRFR1 antagonists might be dependent to some extent on
anxiety trait.
CRFR1 is regarded as a novel target for treating depression, anxiety
and other stress-related disorders. In pre-clinical studies, CRFR1
antagonists appear to be more efﬁcacious in animal models in which
CRF pathways are hyperactivated, whereas they have little effect in
models that are associated with low basal CRF activity (Kehne, 2007).
Our results are consistent with the indication that CRFR1 antagonists
are more effective in reducing anxiety-like behaviors in rodents with
high trait anxiety-like behavior and ⁄ or in those animals previously
exposed to stress (Lancel et al., 2002; Heinrichs & Koob, 2004; Keck
et al., 2005). Speciﬁcally, our results are in line with the recent
proposal that ‘CRFR1 antagonism pharmacotherapy may be especially
effective in the treatment of affectively ill patients experiencing
considerable stress – particularly individuals who are either genetically
predisposed to develop anxiety disorders or have been exposed to high
levels of stress that sensitize subsequent stress responses’ (Hauger
et al., 2006).
Several studies (not always replicated) in depressed suicide victims
have found CRF expression to be increased in different brain regions,
whereas CRFR binding sites in the cortex were decreased, suggesting
a downregulation of CRF signaling in response to excessive release of
the peptide (Risbrough & Stein, 2006). Overexpression of CRF in
genetically engineered mice increases anxiety-like behaviors, whereas
a deﬁciency of CRFR1 is associated with reduced anxiety-like
behavior (Arzt & Holsboer, 2006). Although not a main goal of this
study, we evaluated whether amygdaloid CRF systems might be
affected by CUS in ways that could help explain the blunting of the
electrophysiological response to CRF in chronically stressed animals.
We observed a downregulation of CRFR1 mRNA throughout the
amygdala in high anxious animals, which may be indicative of
hyperactivity of CRF transmission during the chronic stress procedure
in high, but not low, anxious rats. This is consistent with previous
reports indicating a differential modulation of CRF systems by stress
in strains of mice presenting a different vulnerability to stress
(Anisman et al., 2007). However, after 3 weeks of CUS, we did not
observe signiﬁcant alterations in CRF mRNA content in the CeA,
although this does not preclude the possibility that an upregulation of
CRF peptide might have occurred transiently earlier during the stress
procedure. In addition, the potential contribution of CUS-induced
effects on neuronal architecture in the BLA, as previously described
for other chronic stress procedures (Mitra et al., 2005), cannot be
discarded.
In summary, we report evidence for a link between trait anxiety
and reduction in the electrophysiological response of the BLA to
CRF following chronic stress, with highly anxious animals showing
a blunted response. Moreover, we present morphological and
pharmacological evidence that implicates CRFR1 receptors in these
chronic stress-induced alterations and suggests that chronic treat-
ment with a CRFR1 antagonist can protect the brain from some of
the effects of chronic stress. Our study points at CRF and CRFR1
systems as potential mechanistic links between high trait anxiety
and vulnerability to develop depression under conditions of chronic
stress.
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